胶滴肿瘤药敏检测技术的研究进展  

Advances on collagen gel droplet culture drug-sensitivity test

作　　者：梁智[1] 张伟[1] 

机构地区：[1]中国协和医科大学中国医学科学院肿瘤医院肿瘤研究所生物检测中心,北京100021

出　　处：《癌症进展》2005年第5期442-448,共7页Oncology Progress

摘　　要：胶滴肿瘤药敏检测技术(CD-DST)是一种体外肿瘤药敏检测技术,其突出特点是能够排除成纤维细胞对实验的干扰,在体外对抗癌药物的特异性杀伤作用做出客观评价。所需标本量小(3×103个细胞/孔)的特点扩大了该技术的应用范围,弥补了目前其他药敏技术的不足。国外临床研究表明此技术的体外检测结果与临床疗效间存在较好的相关性。CD-DST作为一种先进的体外肿瘤药敏检测技术,对化疗药物杀伤肿瘤细胞有效性的评价、化疗方案的筛选以及肿瘤化疗个体化治疗的推广均具有实际意义。国外研究表明,该技术的应用能够提高恶性肿瘤患者的疗效和临床医师用药的科学水平。Collagen gel droplet culture drug-sensitivity test is a chemosensitivity assay in vitro,which can objectively quantify the anticancer efficacy of drugs without distrubing with fibroblasts by employing image analysis.Furthermore,by using a relatively small number of cells(3×10~3 cell/well),the CD-DST solves some problems inherent in other conventional chemosensitivity assays and extends the applied area at the same time.There was a statistically correlation between clinically reported response rates and that obtained by CD-DST.The CD-DST appears to be useful in exploring the possible combination plots and principles,evaluating the efficacy of existing chemotherapy and optimizing chemotherapy on an individual basis.Therefore,as an advanced chemosensitivity assay,the CD-DST can be used to improve and guide tailored chemotherapy in the future.

关 键 词：肿瘤 药敏检测 胶滴肿瘤药敏检测技术 

分 类 号：R730.5[医药卫生—肿瘤]